Financial HealthCNTX raised $100M in a private placement, resulting in a year-end cash balance of $94.4M, which is expected to support operations into 2027.
Industry AdvancementsThe biopharmaceutical industry is entering a phase of significant advancements in the development of TCEs for solid tumors and that Context Therapeutics stands to benefit from the knowledge gained by the field in developing its three wholly owned programs.
Preclinical DataCT-95 has shown encouraging preclinical data given the membrane-proximal binding to MSLN and that affinity tuning of the MSLN binder should reduce potential liabilities for sMSLN and on-target, off-tumor binding.